Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“upstream regulators of RB have been involved in cancer initiation in patients, both in familial and sporadic cases, and in several organs and tissues25–27.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [26]
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Sherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
Germline p16 mutations in familial melanoma
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., & Dracopoli, N. C. (1994) · Nature Genetics · doi:10.1038/ng0994-15 · Cited by 977
Self-citationAnalysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., et al. (1994) · Nature Genetics · doi:10.1038/ng0994-22 · Cited by 855
Guan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G., & Xiong, Y. (1994) · Genes & Development · doi:10.1101/gad.8.24.2939 · Cited by 714
Research works printed but not linked: 1
- Walker, G.J. et al. .Mutations of the CDKN2/ p16INK4 gene in Australian melanoma kindreds. Hum. Molec. Genet. 4, 1845–1852 (1995).
Cited by
Items 601–700 of 817
Signaling pathways in melanoma biology and new targeted therapeutic approaches
Kiełbik, A., Wawryka, P., Chwiłkowska, A., Saczko, J., & Kulbacka, J. (2019) · Medical Research Journal · doi:10.5603/mrj.a2019.0033 · Cited by 4
“Germline changes in the p16INK4a gene have been identified in approximately half of the families with hereditary melanoma [18].”
BackgroundSingh, K., Baird, M. A., Fischer, R. S., Chaitankar, V., Seifuddin, F., Chen, Y.-C., Tunc, I., Waterman, C. M., & Pirooznia, M. (2020) · Cancers · doi:10.3390/cancers12020458 · Cited by 5
“Inactivating mutations in the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene result in a dysregulated cell cycle promoting melanoma transformation [7,8].”
BackgroundLo, J. A., & Fisher, D. E. (2014) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4939-2143-0_2 · Cited by 4
Targeted Therapies in Melanoma
Fanale, D., Bronte, G., & Russo, A. D. (2015) · Current clinical pathology · doi:10.1007/978-1-4939-2047-1_16 · Cited by 4
Early diagnosis of melanoma: what do we know?
Yee, E., Hoffman, R. M., & Berwick, M. (2007) · Cited by 4
Nishizaki, T., DeVries, S., Chew, K., Goodson, W. H., Ljung, B., Thor, A. D., & Waldman, F. M. (1997) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199708)19:4<250::aid-gcc7>3.0.co;2-w · Cited by 184
Mutation of p16, p21 or cyclin dependent kinase 4 is rare in acute lymphoblastic leukaemia
Qari, M. H., Khalil, S. H., Kambouris, M., & Meyer, B. F. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00974.x · Cited by 4
“Hereditary melanoma families in which the phenotype has been transmitted through a germline mutation of CDK4 have been identified (Zuo et al, 1996).”
BackgroundMethodInfluentialCdk6’s functions are critically regulated by its unique C-terminus
Schirripa, A., Schöppe, H., Nebenfuehr, S., Zojer, M., Klampfl, T., Kugler, V., Schmalzbauer, B. S., Ceylan, H., Uras, I. Z., Scheiblecker, L., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111697 · Cited by 3
Safaroghli‐Azar, A., Mekonnen, L. B., Lenjisa, J. L., Milne, R. W., & Wang, S. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01794-7 · Cited by 5
“These include a point mutation in CDK6 and a miscoding mutation in CDK4 (R24C), both of which attenuate the sensitivity of these CDKs to p16 INK4A in neuroblastoma and familial melanoma [110, 131].”
Arnaut, J. R. M. B., Guimarães, I. D. S., dos Santos, A. C. E., Rodrigues, E. M., Machado, J. R. D. S., & de Melo, A. C. (2023) · International Journal of Dermatology · doi:10.1111/ijd.16742 · Cited by 3
Genetic Testing in the Multidisciplinary Management of Melanoma
Rashid, O. M., & Zager, J. S. (2015) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2015.06.003 · Cited by 3
New Trends in the Susceptibility to Melanoma
Soufir, N., Grandchamp, B., & Basset‐Séguin, N. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-78574-5_19 · Cited by 3
“Interestingly, all mutations occur in codon 24, with two families carrying an R24C change [ 4 ] and four others having an R24H substitution [8, 17, 18].”
BackgroundFerrari, L., & Rüdiger, S. (2019) · Heat shock proteins · doi:10.1007/978-3-030-23158-3_21 · Cited by 3
Noncanonical CDK4 signaling rescues diabetes in a mouse model by promoting β cell differentiation
Stamateris, R. E., Landa-Galván, H. V., Sharma, R. B., Darko, C., Redmond, D., Rane, S. G., & Alonso, L. C. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166490 · Cited by 4
“Specifically, we hypothesized that the Cdk4-R24C nucleotide substitution, which renders CDK4 uninhibitable by INK-family cell cycle inhibitors (23, 24), would rescue lost β cell proliferation and mass in mice lacking IRS2.”
BackgroundEvolution of the Cdk4/6–Cdkn2 system in invertebrates
Yuki, S., Sasaki, S., Yamamoto, Y., Murakami, F., Sakata, K., & Araki, I. (2024) · Genes to Cells · doi:10.1111/gtc.13165 · Cited by 2
Genetic Analysis of the PI3K/AKT/mTOR Signaling Pathway
Hutz, J. (2010) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7rn35v1 · Cited by 3
Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics
Malumbres, M. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-470-4_10 · Cited by 5
Absence of Mutations in the CDKN2 Binding Site of CDK4 in Childhood Acute Lymphoblastic Leukemia
Einsiedel, H. G., Taube, T., Beyermann, B., Dragon, S., Möricke, A., Kebelmann-Betzing, C., Köchling, J., Henze, G., & Seeger, K. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109057941 · Cited by 3
Genodermatoses: Inherited Diseases of the Skin
Smith, F. J. D., & McLean, W. H. I. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-171-4_19 · Cited by 5
Soyer, H. P., Argenziano, G., Hofmann‐Wellenhof, R., & Johr, R. H. (2007) · Springer eBooks · doi:10.1007/978-3-540-35106-1_28 · Cited by 3
Molecular Genetic Pathology of Solid Tumors
Lee, P., Jain, S., Pincus, M. R., & Xu, R. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0974-2.00076-2 · Cited by 3
Simone, P. D., Bottillo, I., Valiante, M., Iorio, A., Bernardo, C. D., Majore, S., D’Angelantonio, D., Valentini, T., Sperduti, I., Piemonte, P., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249432 · Cited by 3
“, CDK4 codon 24) for the CDKN2A gene product [9,10].”
BackgroundGaudy‐Marqueste, C., Monestier, S., & Grob, J. J. (2007) · EMC - Dermatologie · doi:10.1016/s0246-0319(07)44812-9 · Cited by 3
Melanoma: From Tumor-Specific Mutations to a New Molecular Taxonomy and Innovative Therapeutics
Tonnessen-Murray, C. A., & Haass, N. K. (2015) · Springer eBooks · doi:10.1007/978-3-662-45840-2_2 · Cited by 4
Melanoma Techniques and Protocols
Nickoloff, B. J. (2001) · Humana Press eBooks · doi:10.1385/1592591450 · Cited by 3
Kabir, F. M. L., DeInnocentes, P., Bird, A. C., & Bird, R. C. (2021) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-021-00571-9 · Cited by 4
“The altered expression profiles of p16, due to deletion and/or mutation, were first discovered in familial melanomas (Hussussian et al. 1994; Liu et al. 1995; Zuo et al. 1996).”
BackgroundDual-Input Regulation of β-Cell Proliferation by ATF6α and Glucose via E2F1
Landa-Galván, H. V., CASTRO, T. A., Noel, J. J., Llamas, G. A., Sharma, R. B., & Alonso, L. C. (2025) · Diabetes · doi:10.2337/db25-0279 · Cited by 2
Melanoma Epidemiology, Risk Factors, and Clinical Phenotypes
Brachtel, E. F., & David, E. (2011) · InTech eBooks · doi:10.5772/23293 · Cited by 7
“The cyclin dependent kinase 4 (CDK4) enzyme, which is inhibited by p16 binding, is also found to be mutated in small sets of cutaneous melanoma families (Zuo et al., 1996).”
BackgroundColegio, O. R., & Leffell, D. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1788-4.00002-2 · Cited by 2
Musilová, P., Kubı́čková, S., & Rubeš, J. (2002) · Animal Genetics · doi:10.1046/j.1365-2052.2002.00822.x · Cited by 2
No Evidence for Linkage with Melanoma in Italian Melanoma-Prone Families
Kerstann, K. F., Bradford, P. T., Steighner, R. J., Calista, D., Fargnoli, M. C., Peris, K., Scaini, M. C., Menin, C., Ghiorzo, P., Bianchi‐Scarrà, G., et al. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0264 · Cited by 2
Self-citationWhat’s in a cancer syndrome? Genes, phenotype and pathology
Wayte, N., Silva, L. M. D., Chenevix‐Trench, G., & Lakhani, S. R. (2008) · Pathology · doi:10.1080/00313020801911553 · Cited by 3
Discovery and Characterization of Cancer Genetic Susceptibility Alleles
Chanock, S. J., & Ostrander, E. A. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00022-9 · Cited by 3
Modulation of T Lymphocytes by Tumor-Released Survivin
Jutzy, J. M. S., & Wall, N. R. (2017) · Journal of Cancer Biology and Therapeutics · doi:10.18314/gjct.v3i1.122 · Cited by 2
Charlet, J., & Liang, G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800957-4.00016-3 · Cited by 2
Literature review of Notch melanoma receptors
Filho, R. S. D. O., Soares, A. L., Paschoal, F. M., Rezze, G. G., de Oliveira, E. C., Macarenco, R., Buzaid, A. C., & Ferreira, L. M. (2019) · Surgical and Experimental Pathology · doi:10.1186/s42047-019-0052-9 · Cited by 2
Gatalica, Z., Ghazalpour, A., Lilleberg, S. L., Swensen, J. J., & Lynch, H. T. (2016) · Springer eBooks · doi:10.1007/978-1-59745-458-2_22 · Cited by 4
Preclinical Models for Cell Cycle-Targeted Therapies
Malumbres, M. (2006) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-5133-3_13 · Cited by 2
“A point mutation in Cdk4 has also been described in spontaneous and familiar melanomas [9, 10 ].”
BackgroundInherited Gene Mutations in Melanoma
Pho, L. N., Champine, M., Leachman, S. A., & Kohlmann, W. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3554-3_5 · Cited by 2
Alam, M. N. U. (2019) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2019.100208 · Cited by 2
Molecular spectrum of pigmented skin lesions: from nevus to melanoma
Jiang, H. L., Wortsman, J., Matsuoka, L. Y., Granese, J., Carlson, J. A., Mihm, M. C., & Slominski, A. T. (2006) · Expert Review of Dermatology · doi:10.1586/17469872.1.5.679 · Cited by 2
Pharmacogenetic Candidate Genes for Melanoma
Hull, C. M., Larson, A. A., & Leachman, S. A. (2003) · Pharmacogenomics · doi:10.1517/phgs.4.6.753.22819 · Cited by 3
“Although only three families with germline mutations in CDK4 have been identified worldwide [18,32,33], CDKN2A mutations have been identified in 25–40% of familial melanoma kindreds and are also common in many types of sporadic cancers and cell lines.”
BackgroundThe Role Of Fumarase (FH) In Tumorigenesis
Lehtonen, R. (2006) · Helda - University of Helsinki Institutional Repository · Cited by 2
Inhibitory activity of ginger oil against breast cancer cells
Karki, N. (2014) · Louisiana State University · doi:10.31390/gradschool_theses.1714 · Cited by 3
Molecular Genetics of Melanoma Progression
Kohli, J. S., & Bennett, D. C. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0027340 · Cited by 2
Moschos, S. J., Konstantinopoulos, P. A., & Kirkwood, J. M. (2005) · Cancer chemotherapy and biological response modifiers · doi:10.1016/s0921-4410(04)22025-7 · Cited by 2
Grob, J., Gaudy‐Marqueste, C., Cha, K. B., Johnson, T. M., Durham, A. B., Dummer, R., & Goldinger, S. M. (2016) · Wiley eBooks · doi:10.1002/9781118441213.rtd0144 · Cited by 2
CDK4 loss-of-function mutations cause microcephaly and short stature
Schlie, A. V., Leitch, A., Arismendi, M. I., Stok, C., Leal, A. D. C., Parry, D. A., Lerário, A. M., Harley, M. E., Freire, B. L., Carroll, P. L., et al. (2025) · Genes & Development · doi:10.1101/gad.352311.124 · Cited by 3
“Previously, heterozygous germline mutations in CDK4 (R24C or R24H) causing gain of function were described in familial melanoma cases (Zuo et al. 1996; Puntervoll et al. 2013).”
Divergent Pathways to Cutaneous Melanoma
Whiteman, D. C., & Green, A. C. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-994-3_17 · Cited by 2
“Interest in this gene followed from the finding that CDKN2A germline mutations were observed in 40% of affected cases with familial melanoma syndromes ( 69 ,70).”
BackgroundGermline Variants in Childhood Cutaneous Melanoma
Johansson, P. A., Palmer, J. M., Hamilton, H. R., Whiteman, D. C., Pritchard, A. L., & Hayward, N. K. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.02.014 · Cited by 2
Self-citationJohansson, P. A., Palmer, J. M., Brooks, K. M., Chan, H. H., Pritchard, A. L., Wilson, D., Martin, L. K., Guitera, P., & Hayward, N. K. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2026.02.012 · Cited by 1
Self-citationNew horizons in melanoma treatment: targeting molecular pathways.
Soon, C. W. M., Algazi, A. P., Cha, E. N., & DAUD, A. I. (2010) · PubMed · Cited by 1
Mıhçı, E., & Lindor, N. M. (2008) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.32442 · Cited by 1
“Several CMM susceptibility loci have been reported, including the tumor suppressor gene, CDKN2A on chromosome 9p21; the CDK4 oncogene on chromosome12q14; and linkage to both 1p36 and 1p22 in melanoma family studies [Kamb et al., 1994; Zuo et al., 1996; Gillanders et al., 2003; Molven et al., 2005].”
BackgroundCDK4 (cyclin-dependent kinase 4)
Molven, A. (2011) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/38412 · Cited by 1
The aggregation of early-onset melanoma in young Western Australian families
Ward, S. V., Dowty, J. G., Webster, R. J., Cadby, G., Glasson, E. J., Heyworth, J. S., Emery, J. D., Cole, J. M., Millward, M., Wood, F. M., et al. (2015) · Cancer Epidemiology · doi:10.1016/j.canep.2015.03.007 · Cited by 3
“Mutations in CDKN2A, the primary high-penetrance susceptibility gene identified to date, account for only about 20–40% of inherited melanoma cases [4], and predisposing mutations in CDK4 [5,6] and MITF [7,8] have been identified in a smaller number of families.”
BackgroundMolecular Pathogenesis of Human Cancer
Coleman, W. B., & Tsongalis, G. J. (2006) · Humana Press eBooks · doi:10.1385/1-59259-928-1:349 · Cited by 1
DNA damage response genes and chromosome 11q21-q24 candidate tumor suppressor genes in breast cancer
Allinen, M. (2002) · Cited by 1
Borroni, R. G., Manganoni, A. M., Grassi, S., Grasso, M., Diegoli, M., Giorgianni, C., Favalli, V., Pavoni, L., Cespa, M., & Arbustini, E. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000324 · Cited by 3
Gilbert, F., & Kauff, N. D. (2000) · Genetic Testing · doi:10.1089/10906570050501588 · Cited by 4
Aktary, Z., McMahon, M., & Larue, L. (2019) · Springer eBooks · doi:10.1007/978-1-4614-7147-9_32 · Cited by 1
Moira, R. J., & Stephen, P. S. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-963-9_77 · Cited by 1
Melanoma and Glioblastoma—Not a Serendipitous Association
Oh, K. S., & Mahalingam, M. (2023) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000393 · Cited by 1
Publication trends and hot topics in dysplastic nevus research: A 30-year bibliometric analysis
Özmen, H. İ. (2023) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1304a266 · Cited by 1
Pyeritz, R. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-812531-1.00014-2 · Cited by 1
Kamb, A., & McCormack, K. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-230-2_8 · Cited by 1
Pathogenesis of Malignant Melanoma
Hoek, K. S. (2010) · Springer eBooks · doi:10.1007/978-3-642-05072-5_9 · Cited by 1
“For these only p16 and Cdk4 have been identified as high-risk genes and, while only six families present with a germline mutation in Cdk4 which abrogates p16 binding, approximately one-third of all other familial melanomas correlate with an inherited p16-inactivating deletion or mutation [35, 63, 70, 89, 108].”
BackgroundPigmentation, DNA Repair, and Candidate Genes
Landi, M. T. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-994-3_18 · Cited by 1
The Digital age of Melanoma Management: Detection and Diagnostics
Fogel, A. L., & Sarin, K. Y. (2015) · Melanoma Management · doi:10.2217/mmt.15.31 · Cited by 2
Inherited Contributions to Melanoma Risk
Brown, K. M., MacGregor, S., & Law, M. H. (2017) · Springer eBooks · doi:10.1007/978-1-4614-7322-0_31-1 · Cited by 1
Melanomics: Comprehensive Molecular Analysis of Normal and Neoplastic Melanocytes
Nguyen, X. T. S., & Watson, I. R. (2018) · Springer eBooks · doi:10.1007/978-1-4614-7322-0_30-1 · Cited by 1
Role of Cell Cycle Control and Cyclin-Dependent Kinases in Breast Cancer
Senderowicz, A. M. (2002) · Breast Disease · doi:10.3233/bd-2002-15105 · Cited by 3
“As was mentioned above, CDK4 mutations were also identified in patients with familial melanoma [25,78,79].”
The role of genetics in the prevention of skin cancer
Whiteman, D. C., & Neale, R. Ε. (2004) · Cancer prevention, cancer causes · doi:10.1007/978-94-017-0511-0_7 · Cited by 2
“To date, three melanoma families have been identified with mutations in the CDK4 gene [15].”
BackgroundMolecular-Targeted Therapy for Melanoma
RUSSO, A. E., Bevelacqua, Y., Marconi, A., Veronesi, A., & Libra, M. (2011) · Springer eBooks · doi:10.1007/978-1-60761-433-3_20 · Cited by 1
Prognostic factors of primary cutaneous melanoma
Ilmonen, S. (2005) · Työväentutkimus Vuosikirja · Cited by 1
DEFECTS IN TRICARBOXYLIC ACID CYCLE ENZYMES FUMARATE HYDRATASE AND SUCCINATE DEHYDROGENASE IN CANCER
Ylisaukko‐oja, S. K. (2007) · Helda - University of Helsinki Institutional Repository · Cited by 1
Intracellular Signaling in Cancer
Thakore, C. U., Lehmann, B. D., McCubrey, J. A., & Terrian, D. M. (2006) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.200400106 · Cited by 1
Lluria-Prevatt, M., Dickinson, S. E., & Alberts, D. S. (2013) · Springer eBooks · doi:10.1007/978-3-642-38983-2_12 · Cited by 1
UV Response of Mammalian p53 Tumor Supressor Gene
Mälkönen, T. (1999) · Helda - University of Helsinki Institutional Repository · Cited by 1
Molecular Mutations in Human Neoplastic Disease
Coleman, W. B., & Tsongalis, G. J. (1997) · doi:10.1007/978-1-4757-2588-9_14 · Cited by 1
Zhuang, S., Wiseman, R. W., & Söderkvist, P. (2000) · Cancer Letters · doi:10.1016/s0304-3835(99)00447-4 · Cited by 1
Mutation and Polymorphism Report
Moore, P. S., Zamboni, G., Falconi, M., Bassi, C., & Scarpa, A. (2000) · Cited by 1
Genetics, prevention and screening for melanoma
Hershock, D. M. (2005) · Cancer chemotherapy and biological response modifiers · doi:10.1016/s0921-4410(04)22031-2 · Cited by 1
Dubus, P. R., Malumbres, M., & Ortega, S. (2006) · Enzyme inhibitors series/CRC enzyme inhibitors series · doi:10.1201/9781420005400.ch3 · Cited by 1
The Biology of Skin Cancer Invasion and Metastasis
Berrios, R. L., & Arbiser, J. L. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1788-4.00001-0 · Cited by 1
Human melanoma antigens recognized by CD8 T cells
Kawakami, Y. (2003) · CRC Press eBooks · doi:10.1201/9780203217658-12 · Cited by 2
Hendricks, W. P. D., Sekulić, A., Bryce, A. H., Murtaza, M., Ramos, P., & Trent, J. M. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm007 · Cited by 1
Human melanoma antigens recognized by CD8+ T cells
Kawakami, Y. (2003) · CRC Press eBooks · doi:10.1201/9780203217658.ch4 · Cited by 1
Newton‐Bishop, J. (2000) · Hospital Medicine · doi:10.12968/hosp.2000.61.2.1273 · Cited by 1
Molecular Diagnosis of Melanoma
Ortiz‐Urda, S., Ho, W. W.-S., & Lee, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-59128-0_2 · Cited by 1
Genetik des familiären Melanoms
Peris, K., & Fargnoli, M. C. (2006) · Springer eBooks · doi:10.1007/3-540-28988-7_1 · Cited by 1
Shared and Individual CTL-Defined Antigens on Human Melanoma Cells
Wölfel, T., Schneider, J., Hauer, M., Wölfel, C., & Herr, W. (1997) · Springer eBooks · doi:10.1007/978-3-642-60562-8_2
Molecular Diagnosis of Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
Loukola, A. (2000) · Helda - University of Helsinki Institutional Repository · Cited by 1
Matthews, D. J., & Gerritsen, M. E. (2010) · Wiley eBooks · doi:10.1002/9780470555293.ch6
An Overview of Important Genetic Aspects in Melanoma
Rohinton, S. (2013) · InTech eBooks · doi:10.5772/55257 · Cited by 1
“Using linkage analysis of families with high melanoma incidences, the first melanoma incidence susceptibility gene, CDK2N2A was identified at chromosome 9p21 [25,26].”
BackgroundPresence of BRAF V600E Mutation in Nevus Cases
ÇETİN, A., Kökten, Ş. Ç., Demirkan, N. Ç., Şatıroğlu-Tufan, N. L., Tufan, A. C., & Bağcı, H. (2010) · Turkiye Klinikleri Journal of Medical Sciences · doi:10.5336/medsci.2008-9201
A Genetic Basis for Luminal and Basal-Type Breast Cancer
Hollestelle, A. (2009) · RePub (Erasmus University Rotterdam)
Familial Melanoma in Italy: A Review
Funari, G., Menin, C., Elefanti, L., D’Andrea, E., & Chiara, M. L. D. (2011) · InTech eBooks · doi:10.5772/21801 · Cited by 2
CHEK2 in Breast and Colorectal Cancer
Kilpivaara, O. (2007) · Helda - University of Helsinki Institutional Repository
Metadata
- Authors
- Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- Venue
- Nature Genetics
- Published
- 1996-01
- Volume
- 12
- Issue
- 1
- Pages
- 97-99
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2051506850
- Cited by
- 818
- References
- 29
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 11 · 2023: 13 · 2022: 13 · 2021: 19 · 2020: 19 · 2019: 23 · 2018: 24 · 2017: 36 · 2016: 24 · 2015: 27 · 2014: 32 · 2013: 30 · 2012: 19
- FWCI
- 14.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- CDK4, germline mutations, familial melanoma, cyclin-dependent kinases, cyclin D, retinoblastoma protein phosphorylation, G1 cell cycle checkpoint, hereditary melanoma, tumor-specific antigens
- MeSH terms
- Base Sequence, Carrier Proteins, Female, Humans, Male, Melanoma, Molecular Sequence Data, Pedigree, Proto-Oncogene Proteins, DNA Primers, Polymorphism, Single-Stranded Conformational, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.